Search Within

Margaret Kathleen Callahan

Formats
  1. Journal Article (104)
  2. Meeting Abstract (83)
  3. Editorial (4)
  4. Book Section (2)
  5. Research Letter (2)
  6. Guidelines (1)
  7. Review (1)
Groups
  1. Department of Medicine (197)
  2. Melanoma and Immunotherapeutics Service (197)
  3. Solid Tumor Oncology Division (197)
  4. GSK Faculty (123)
  5. Melanoma Disease Management Team (107)
  6. Hematologic Malignancies, Division of (76)

More Groups

People
  1. Jedd Wolchok (113)
  2. Michael Postow (95)
  3. Paul Chapman (49)
  4. Alexander Shoushtari (45)
  5. Katherine Panageas (38)
  6. Parisa Momtaz (29)

More People

Years
  1. 2025 (3)
  2. 2024 (6)
  3. 2023 (9)
  4. 2022 (13)
  5. 2021 (11)
  6. 2020 (19)

More Years

Publications
  1. Journal of Clinical Oncology (60)
  2. Journal for ImmunoTherapy of Cancer (17)
  3. Science Translational Medicine (10)
  4. Annals of Oncology (7)
  5. Clinical Cancer Research (7)
  6. New England Journal of Medicine (7)

More Publications

Publishers
  1. American Society of Clinical Oncology (64)
  2. Biomed Central Ltd (17)
  3. Elsevier Inc. (17)
  4. American Association for Cancer Research (15)
  5. Oxford University Press (15)
  6. Nature Publishing Group (11)

More Publishers

Results (197)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Treatment outcomes of immune-related cutaneous adverse events
    Journal Article

    Phillips, G. S.; Wu, J.; Hellmann, M. D.; Postow, M. A.; Rizvi, N. A.; Freites-Martinez, A.; Chan, D.; Dusza, S.; Motzer, R. J.; Rosenberg, J. E.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Recruit or reboot? How does anti-PD-1 therapy change tumor-infiltrating lymphocytes?
    Editorial

    Callahan, M. K.; Wolchok, J. D.
    Cancer Cell (2019)

    Fulltext@MSK | Save
  • Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: CheckMate 032 nivolumab 1 mg/kg plus ipilimumab 3 mg/kg expansion cohort results
    Journal Article

    Sharma, P.; Siefker-Radtke, A.; de Braud, F.; Basso, U.; Calvo, E.; Bono, P.; Morse, M. A.; Ascierto, P. A.; Lopez-Martin, J.; Brossart, P.; more...
    Journal of Clinical Oncology (2019)

    Fulltext@MSK | Save
  • Myocarditis surveillance in patients with advanced melanoma on combination immune checkpoint inhibitor therapy: The Memorial Sloan Kettering Cancer Center experience
    Research Letter

    Lee Chuy, K.; Oikonomou, E. K.; Postow, M. A.; Callahan, M. K.; Chapman, P. B.; Shoushtari, A. N.; Neilan, T. G.; Fradley, M. G.; Ramanathan, L. V.; Wolchok, J. D.; more...
    The Oncologist (2019)

    Fulltext@MSK | Save
  • Rational design of anti-GITR-based combination immunotherapy
    Journal Article

    Zappasodi, R.; Sirard, C.; Li, Y.; Budhu, S.; Abu-Akeel, M.; Liu, C.; Yang, X.; Zhong, H.; Newman, W.; Qi, J.; more...
    Nature Medicine (2019)

    Fulltext@MSK | Save
  • Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade
    Journal Article

    Boland, J. L.; Zhou, Q.; Martin, M.; Callahan, M. K.; Konner, J.; O'Cearbhaill, R. E.; Friedman, C. F.; Tew, W.; Makker, V.; Grisham, R. N.; more...
    Gynecologic Oncology (2019)

    Fulltext@MSK | Save
  • ICONIC: Biologic and clinical activity of first in class ICOS agonist antibody JTX-2011+/- nivolumab (nivo) in patients (pts) with advanced cancers
    Meeting Abstract

    Yap, T. A.; Burris, H. A.; Kummar, S.; Falchook, G. S.; Pachynski, R. K.; LoRusso, P.; Tykodi, S. S.; Gibney, G. T.; Gainor, J. F.; Rahma, O. E.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Treatment outcomes of cutaneous adverse events to immune checkpoint inhibitors
    Meeting Abstract

    Wu, J.; Freites-Martinez, A.; Hellmann, M. D.; Rosenberg, J. E.; Motzer, R. J.; Chapman, P. B.; Rizvi, N. A.; Geskin, L. J.; Reed, V. A.; Dusza, S. W.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Tumor mutational burden, clinical features, and outcomes to PD-1 mono- and combination therapy in patients with cutaneous and unknown primary melanoma
    Meeting Abstract

    Shoushtari, A. N.; Armenia, J.; Arora, A.; Rojas-Zamalloa, J.; Warner, A. B.; Derr, M.; Postow, M. A.; Callahan, M. K.; Momtaz, P.; Coit, D. G.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Anti-CD27 agonist antibody varlilumab (varli) with nivolumab (nivo) for colorectal (CRC) and ovarian (OVA) cancer: Phase (Ph) 1/2 clinical trial results
    Meeting Abstract

    Sanborn, R. E.; Pishvaian, M. J.; Callahan, M. K.; Weise, A. M.; Sikic, B. I.; Rahma, O. E.; Cho, D. C.; Rizvi, N. A.; Bitting, R. L.; Starodub, A.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save